Drug delivery to the inflamed intestinal mucosa – targeting technologies and human cell culture models for better therapies of IBD

Hartwig, Olga; Boushehri, Maryam A. Shetab; Shalaby, Karim S.; Loretz, Brigitta; Lamprecht, Alf; Lehr, Claus‐Michael

doi:10.1016/j.addr.2021.113828

Cited by 44 publications

(30 citation statements)

References 346 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 School of Basic Medical Sciences, Xian Key Laboratory of Immune Related Diseases, Xian Jiaotong University, Xi'an 710061, Shaanxi, China. 3 Britton Chance Center for Biomedical Photonics at Wuhan National Laboratory for Optoelectronics -Hubei Bioinformatics & Molecular Imaging Key Laboratory, Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, Hubei, China. 4 Department of Emergency and Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.…”

Section: Supplementary Informationmentioning

confidence: 99%

“…The pathogenesis of IBD is unclear and may be attributed to the interference of many factors, including environment, genetics, gastrointestinal dysbiosis, and infection [1,2]. Although drug-based therapy can control inflammation to some extent, it is almost impossible to cure it completely [3]. Intestinal fibrosis is a known complication of IBD and can be present in both UC and CD, but is more common in CD.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Orally administration of cerium oxide nanozyme for computed tomography imaging and anti-inflammatory/anti-fibrotic therapy of inflammatory bowel disease

et al. 2023

View full text Add to dashboard Cite

Background Inflammatory bowel disease (IBD) is a chronic nonspecific disease with unknown etiology. Currently, the anti-inflammatory therapeutic approaches have achieved a certain extent of effects in terms of inflammation alleviation. Still, the final pathological outcome of intestinal fibrosis has not been effectively improved yet. Results In this study, dextran-coated cerium oxide (D-CeO2) nanozyme with superoxide dismutase (SOD) and catalase (CAT) activities was synthesized by chemical precipitation. Our results showed that D-CeO2 could efficiently scavenge reactive oxide species (ROS) as well as downregulate the pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, and iNOS) to protect cells from H2O2-induced oxidative damage. Moreover, D-CeO2 could suppress the expression of fibrosis-related gene levels, such as α-SMA, and Collagen 1/3, demonstrating the anti-fibrotic effect. In both TBNS- and DSS-induced colitis models, oral administration of D-CeO2 in chitosan/alginate hydrogel alleviated intestinal inflammation, reduced colonic damage by scavenging ROS, and decreased inflammatory factor levels. Notably, our findings also suggested that D-CeO2 reduced fibrosis-related cytokine levels, predicting a contribution to alleviating colonic fibrosis. Meanwhile, D-CeO2 could also be employed as a CT contrast agent for noninvasive gastrointestinal tract (GIT) imaging. Conclusion We introduced cerium oxide nanozyme as a novel therapeutic approach with computed tomography (CT)-guided anti-inflammatory and anti-fibrotic therapy for the management of IBD. Collectively, without appreciable systemic toxicity, D-CeO2 held the promise of integrated applications for diagnosis and therapy, pioneering the exploration of nanozymes with ROS scavenging capacity in the anti-fibrotic treatment of IBD.

show abstract

Section: Supplementary Informationmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Orally administration of cerium oxide nanozyme for computed tomography imaging and anti-inflammatory/anti-fibrotic therapy of inflammatory bowel disease

et al. 2023

View full text Add to dashboard Cite

show abstract

“…139 In particular, Crohn's disease can affect all portions of the GI tract in a non-uniform distribution, which can exaggerate immune responses throughout the barrier and compromise its integrity. 140 Specific to the disease state, there are also changes in pH within the GI tract where some patients experiencing Crohn's disease have a colon pH between 5 and 7, whereas ulcerative colitis patients can have a pH of 2.7–5.5; for comparison a healthy patient generally has a colon pH of 6.2–7.4. 141 Notably, the lower pH may present an additional barrier to orally administered drugs, and biologics in particular.…”

Section: Gastrointestinal Mucus Barriermentioning

confidence: 99%

Modulation of engineered nanomaterial interactions with organ barriers for enhanced drug transport

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Both are caused by an overactive immune response to gut microbiota in genetically vulnerable individuals [ 26 ]. Ulcerative colitis is limited to the colon, whereas Crohn’s disease is regarded as inflammation in the whole gastrointestinal tract in a non-continuous fashion [ 5 , 27 ]. The precise etiology of IBD has been studied for decades and remains unclear.…”

Section: Oxidative Stress and Ibdmentioning

confidence: 99%

Oxidative Stress and Antioxidant Nanotherapeutic Approaches for Inflammatory Bowel Disease

Liu

Wang

et al. 2021

Biomedicines

View full text Add to dashboard Cite

Oxidative stress, caused by the accumulation of reactive species, is associated with the initiation and progress of inflammatory bowel disease (IBD). The investigation of antioxidants to target overexpressed reactive species and modulate oxidant stress pathways becomes an important therapeutic option. Nowadays, antioxidative nanotechnology has emerged as a novel strategy. The nanocarriers have shown many advantages in comparison with conventional antioxidants, owing to their on-site accumulation, stability of antioxidants, and most importantly, intrinsic multiple reactive species scavenging or catalyzing properties. This review concludes an up-to-date summary of IBD nanomedicines according to the classification of the delivered antioxidants. Moreover, the concerns and future perspectives in this study field are also discussed.

show abstract

Drug delivery to the inflamed intestinal mucosa – targeting technologies and human cell culture models for better therapies of IBD

Cited by 44 publications

References 346 publications

Orally administration of cerium oxide nanozyme for computed tomography imaging and anti-inflammatory/anti-fibrotic therapy of inflammatory bowel disease

Orally administration of cerium oxide nanozyme for computed tomography imaging and anti-inflammatory/anti-fibrotic therapy of inflammatory bowel disease

Modulation of engineered nanomaterial interactions with organ barriers for enhanced drug transport

Oxidative Stress and Antioxidant Nanotherapeutic Approaches for Inflammatory Bowel Disease

Contact Info

Product

Resources

About